U.S. digital health companies secured $3 billion in funding across 122 deals in the first quarter of 2025, according to an April 7 report from Rock Health.
Here are five key findings from the report:
- Compared to the previous quarter, Q1 saw more capital invested across about the same number of deals, increasing the average deal size from $15.5 million to $24.4 million.
- Small, early-stage startups accounted for most deals in the first quarter.
- The largest funding rounds were led by major companies or startups backed by significant investors.
- Seed, Series A and Series B rounds comprised 83% of labeled deals, similar to 2024’s 86%.
- Notable large early-stage rounds included Achira’s $33 million seed round, OpenEvidence’s $75 million Series A and Hippocratic AI’s $141 million Series B.
Late-stage megadeals also returned in Q1 2025. Only five Series D or later rounds were recorded, but three surpassed $100 million: Innovaccer ($275 million), Abridge ($250 million) and Qventus ($105 million).
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
